The invention provides an oral formulation for dietary supplementation comprising a binder and a mineral complex consisting essentially of a natural basaltic deposit having an average particle size ranging from about 10 to about 6000 mesh and comprising about 40 wt. % to about 60 wt. % Si0.sub.2, about 6 wt. % to about 16 wt. % Fe.sub.20.sub.3, about 4 wt. % to about 12 wt. %. CaO, and about 2 wt. % to about 8 wt. % MgO. Methods of formulating and using the aforesaid oral formulation also are provided.

The present invention provides a physically and chemically stable pharmaceutical liquid composition including sodium picosulfate, magnesium oxide, citric acid and malic acid and methods of making and using such a composition.

The present invention provides a physically and chemically stable pharmaceutical liquid composition including sodium picosulfate, magnesium oxide, citric acid and malic acid and methods of making and using such a composition.

The invention relates to a highly flowable crosslinkable medical or dental composition comprising a crosslinkable compound, a polymerization initiator and a heterogeneous radiopacifier. Also described is a crosslinked polymer composition obtainable by crosslinking said highly flowable, crosslinkable medical or dental composition and the use of said highly flowable crosslinkable medical or dental composition to fill cavities or hollow structures in human or animal subjects.

The invention provides one or more agent selected from nitric oxide (NO), a nitric oxide generating composition, a combination or combinable association of ingredients for a nitric oxide generating composition, and mixtures thereof, for use as an antibacterial agent against tuberculosis and Mycobacterium tuberculosis.

The invention provides one or more agent selected from nitric oxide (NO), a nitric oxide generating composition, a combination or combinable association of ingredients for a nitric oxide generating composition, and mixtures thereof, for use as an antibacterial agent against tuberculosis and Mycobacterium tuberculosis.

A liquid oral pharmaceutical dosage form, comprising pharmacologically effective amounts of at least one histamine H2-receptor antagonist in a hydrophobic/lipophilic liquid substantially free from water comprising at least one viscosity enhancing agent, and pharmacologically effective amounts of one or more antacid(s) in a liquid comprising at least one viscosity enhancing agent and at least one flavor, wherein the two liquids are physically separated from each other and wherein the two liquids have matching rheological profiles and a package comprising multiple liquid oral dosage forms as well as a method of treating a gastric disease or disorder by use of the liquid oral pharmaceutical dosage form.

A liquid oral pharmaceutical dosage form, comprising pharmacologically effective amounts of at least one histamine H2-receptor antagonist in a hydrophobic/lipophilic liquid substantially free from water comprising at least one viscosity enhancing agent, and pharmacologically effective amounts of one or more antacid(s) in a liquid comprising at least one viscosity enhancing agent and at least one flavor, wherein the two liquids are physically separated from each other and wherein the two liquids have matching rheological profiles and a package comprising multiple liquid oral dosage forms as well as a method of treating a gastric disease or disorder by use of the liquid oral pharmaceutical dosage form.

A liquid oral pharmaceutical dosage form, comprising pharmacologically effective amounts of at least one histamine H2-receptor antagonist in a hydrophobic/lipophilic liquid substantially free from water comprising at least one viscosity enhancing agent, and pharmacologically effective amounts of one or more antacid(s) in a liquid comprising at least one viscosity enhancing agent and at least one flavor, wherein the two liquids are physically separated from each other and wherein the two liquids have matching rheological profiles and a package comprising multiple liquid oral dosage forms as well as a method of treating a gastric disease or disorder by use of the liquid oral pharmaceutical dosage form.

Provided are: a glass composition for wound care, which promotes a wound healing process by providing a moist environment and nutrients necessary for growth of epidermal cells, and which has bactericidal properties for preventing critical fixing of bacteria to a wound surface and infection with bacteria; and a wound covering material that uses the glass composition. The glass composition contains, by mass % in terms of oxides, 5 to 70% of SiO.sub.2, 0 to 10% of Al.sub.2O.sub.3, 5 to 40.0% of B.sub.2O.sub.3, and 1 to 50% of CaO.